Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies.

× No keyword cloud information.

17 in total

1. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute.

Authors: Sidney C Smith; Jerilyn Allen; Steven N Blair; Robert O Bonow; Lawrence M Brass; Gregg C Fonarow; Scott M Grundy; Loren Hiratzka; Daniel Jones; Harlan M Krumholz; Lori Mosca; Thomas Pearson; Marc A Pfeffer; Kathryn A Taubert
Journal: J Am Coll Cardiol Date: 2006-05-16 Impact factor: 24.094

Review 2. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.

Authors: Robert S Rosenson
Journal: Am J Cardiol Date: 2006-12-22 Impact factor: 2.778

Review 3. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.

Authors: John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum
Journal: J Am Coll Cardiol Date: 2008-04-15 Impact factor: 24.094

4. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial.

Authors: James D Otvos; Irina Shalaurova; David S Freedman; Robert S Rosenson
Journal: Atherosclerosis Date: 2002-01 Impact factor: 5.162

5. Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content.

Authors: M L Grønholdt; B G Nordestgaard; B M Wiebe; J E Wilhjelm; H Sillesen
Journal: Circulation Date: 1998 Jan 6-13 Impact factor: 29.690

6. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl.

Authors: William C Cromwell; James D Otvos
Journal: Am J Cardiol Date: 2006-10-18 Impact factor: 2.778

Review 7. Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines.

Authors: D B Hunninghake
Journal: Am J Cardiol Date: 2001-10-18 Impact factor: 2.778

8. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

Authors: Robert S Rosenson; David A Wolff; Anna L Huskin; Irene B Helenowski; Alfred W Rademaker
Journal: Diabetes Care Date: 2007-05-04 Impact factor: 19.112

9. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

Authors: R G Bakker-Arkema; M H Davidson; R J Goldstein; J Davignon; J L Isaacsohn; S R Weiss; L M Keilson; W V Brown; V T Miller; L J Shurzinske; D M Black
Journal: JAMA Date: 1996-01-10 Impact factor: 56.272

10. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.

Authors: Robert S Rosenson; Anna L Huskin; David A Wolff; Irene B Helenowski; Alfred W Rademaker
Journal: Atherosclerosis Date: 2008-02-01 Impact factor: 5.162